
|Articles|January 17, 2014
Lonza Signs Agreement with Index Ventures for Biological Products
Author(s)BioPharm International Editors
Lonza signs an agreement with Index Ventures for the development and manufacture of biologics for portfolio companies.
Advertisement
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Top 10 BioPharm International Articles of 2025
2
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
3
Biopharma’s 2025 Transformation: A Recap of Our Top 10 Articles
4
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
5




